3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 4
1
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Virus Diseases
1
Urinary Bladder Neoplasms
1
Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma in Situ
1
Adenoviridae Infections
1
Interventions
Cisplatin
29
Carboplatin
28
Gemcitabine
27
Paclitaxel
26
pembrolizumab
24
Capecitabine
16
Pemetrexed
15
Bevacizumab
15
Docetaxel
14
Oxaliplatin
13
Fluorouracil
12
Drug Therapy
12
Nivolumab
10
130-nm albumin-bound paclitaxel
9
anlotinib
7
Trastuzumab
7
Injections
7
Rituximab
6
atezolizumab
5
Temozolomide
5
Leucovorin
5
Ipilimumab
5
venetoclax
4
Lenalidomide
4
Irinotecan
4
Interferon alpha-2
4
Folfox protocol
4
Dexamethasone
4
Albumin-Bound Paclitaxel
4
sintilimab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
INDUSTRY
×
Interferons
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled